Healthcare provider profile · identity verified

Silvia Labes, M.D.

Internal Medicine · YAKIMA, WA · NPI 1972531531

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	640	160
Atorvastatin Calcium	Atorvastatin Calcium	527	140
Rosuvastatin Calcium	Rosuvastatin Calcium	299	82
Omeprazole	Omeprazole	251	75
Losartan Potassium	Losartan Potassium	246	74
Metoprolol Succinate	Metoprolol Succinate	190	59
Amlodipine Besylate	Amlodipine Besylate	172	51
Trazodone Hcl	Trazodone Hcl	170	51
Lisinopril	Lisinopril	165	52
Citalopram Hbr	Citalopram Hydrobromide	141	35
Metformin Hcl Er	Metformin Hcl	130	41
Simvastatin	Simvastatin	128	38
Escitalopram Oxalate	Escitalopram Oxalate	121	34
Eliquis	Apixaban	116	26
Alendronate Sodium	Alendronate Sodium	108	34
Furosemide	Furosemide	101	31
Potassium Chloride	Potassium Chloride	99	35
Gabapentin	Gabapentin	95	33
Carvedilol	Carvedilol	91	22
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	86	32
Valsartan	Valsartan	85	26
Bupropion Xl	Bupropion Hcl	79	21
Hydrochlorothiazide	Hydrochlorothiazide	76	20
Donepezil Hcl	Donepezil Hcl	72	17
Sertraline Hcl	Sertraline Hcl	70	21
Estradiol	Estradiol	69	32
Mirtazapine	Mirtazapine	68	23
Pantoprazole Sodium	Pantoprazole Sodium	68	18
Lorazepam	Lorazepam	66	25
Tramadol Hcl	Tramadol Hcl	60	24
Duloxetine Hcl	Duloxetine Hcl	56	17
Montelukast Sodium	Montelukast Sodium	56	18
Pravastatin Sodium	Pravastatin Sodium	53	16
Prednisone	Prednisone	53	31
Albuterol Sulfate Hfa	Albuterol Sulfate	52	30
Celecoxib	Celecoxib	51	17
Allopurinol	Allopurinol	50	14
Myrbetriq	Mirabegron	48	12
Warfarin Sodium	Warfarin Sodium	48	16
Fluoxetine Hcl	Fluoxetine Hcl	47	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	47	14
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	43	16
Valacyclovir	Valacyclovir Hcl	43	22
Metformin Hcl	Metformin Hcl	42	13
Zolpidem Tartrate	Zolpidem Tartrate	41	22
Alprazolam	Alprazolam	40	18
Benazepril Hcl	Benazepril Hcl	39	13
Metoprolol Tartrate	Metoprolol Tartrate	39	14
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	39	11
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	39	30
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	39	11
Glimepiride	Glimepiride	38	suppressed
Meloxicam	Meloxicam	38	12
Cephalexin	Cephalexin	37	29
Amitriptyline Hcl	Amitriptyline Hcl	36	suppressed
Propranolol Hcl Er	Propranolol Hcl	36	suppressed
Oxycodone Hcl	Oxycodone Hcl	34	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	33	13
Mounjaro	Tirzepatide	33	suppressed
Ozempic	Semaglutide	32	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	31	suppressed
Spironolactone	Spironolactone	30	suppressed
Paroxetine Hcl	Paroxetine Hcl	29	suppressed
Buspirone Hcl	Buspirone Hcl	28	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	28	suppressed
Atenolol	Atenolol	27	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	27	suppressed
Ondansetron Hcl	Ondansetron Hcl	27	suppressed
Tizanidine Hcl	Tizanidine Hcl	27	15
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	27	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	26	13
Famotidine	Famotidine	26	suppressed
Ipratropium Bromide	Ipratropium Bromide	26	15
Synthroid	Levothyroxine Sodium	24	suppressed
Memantine Hcl	Memantine Hcl	23	suppressed
Raloxifene Hcl	Raloxifene Hcl	23	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	22	suppressed
Pregabalin	Pregabalin	22	11
Nifedipine Er	Nifedipine	21	suppressed
Fluticasone Propionate	Fluticasone Propionate	20	suppressed
Lovastatin	Lovastatin	20	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	20	suppressed
Baclofen	Baclofen	19	suppressed
Methocarbamol	Methocarbamol	19	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	18	18
Clopidogrel	Clopidogrel Bisulfate	18	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	18	suppressed
Jardiance	Empagliflozin	18	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	18	suppressed
Breo Ellipta	Fluticasone/Vilanterol	17	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	17	suppressed
Nystatin	Nystatin	17	suppressed
Xarelto	Rivaroxaban	17	suppressed
Chlorthalidone	Chlorthalidone	16	suppressed
Farxiga	Dapagliflozin Propanediol	16	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	16	suppressed
Solifenacin Succinate	Solifenacin Succinate	16	suppressed
Digoxin	Digoxin	15	suppressed
Doxepin Hcl	Doxepin Hcl	15	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	15	12
Azelastine Hcl	Azelastine Hcl	14	suppressed
Irbesartan	Irbesartan	14	suppressed
Torsemide	Torsemide	14	suppressed
Acyclovir	Acyclovir	13	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	13	suppressed
Clonazepam	Clonazepam	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Symbicort	Budesonide/Formoterol Fumarate	13	suppressed
Azithromycin	Azithromycin	12	11
Estradiol (Once Weekly)	Estradiol	12	suppressed
Fluconazole	Fluconazole	12	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	12	suppressed
Premarin	Estrogens, Conjugated	12	suppressed
Diazepam	Diazepam	11	suppressed
Diclofenac Sodium	Diclofenac Sodium	11	suppressed
Diltiazem 24hr Er (La)	Diltiazem Hcl	11	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	11	suppressed
Estring	Estradiol	11	suppressed
Gemtesa	Vibegron	11	suppressed
Glipizide Er	Glipizide	11	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	11	suppressed
Neupro	Rotigotine	11	suppressed
Repatha Syringe	Evolocumab	11	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	11	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	11	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error